Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biomarin Pharmaceuticals (NQ: BMRN )

84.98 +2.11 (+2.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 885,541
Open 82.92
Bid (Size) 81.18 (1)
Ask (Size) 87.00 (1)
Prev. Close 82.87
Today's Range 82.70 - 85.06
52wk Range 70.73 - 94.20
Shares Outstanding 183,352,255
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
What 4 Analyst Ratings Have To Say About Biomarin Pharmaceutical
Analysts have provided the following ratings for Biomarin Pharmaceutical (NASDAQ:BMRN) within the last quarter: 
Via Benzinga

Performance

YTD
-4.90%
-4.90%
1 Month
+9.67%
+9.67%
3 Month
+5.85%
+5.85%
6 Month
-4.90%
-4.90%
1 Year
+0.48%
+0.48%

More News

Read More
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
The Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru's Pre-EUA Meeting, Conference Presentations And More
Via Benzinga
BioMarin Stock Dives As FDA Questions The Safety Of Its Gene Therapy
Via Investor's Business Daily
BioMarin Sells Priority Review Voucher For $110M
Via Benzinga
BioMarin Achieves Record Q1 Sales Driven By Recently Approved Achondroplasia Therapy
Via Benzinga
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
Via Benzinga
Biomarin Pharmaceutical Earnings Preview
Via Benzinga
10 Biggest Price Target Changes For Monday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022
Via Benzinga
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
Via Benzinga
A Bearish Sign Appears On Biomarin Pharmaceutical's Chart
Via Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
Via InvestorPlace
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
Via Benzinga
BioMarin Clocks Flat Q4 Sales Despite Erosion oF US Kuvan Market
Via Benzinga
Recap: Biomarin Pharmaceutical Q4 Earnings
Via Benzinga
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
Via Benzinga
FDA Asks For More Data To Resolve BioMarin's Gene Therapy Clinical Hold
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Via Benzinga
Bear Market Bets In Biotech
Via Talk Markets
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of BioMarin Pharmaceutical Inc.
Via Newsfile
Exposures Product Safety
Futures Resume Tumbling After Yields Spike To New 2 Year High
Via Talk Markets
BioMarin's Hemophilia Gene Therapy Meets Efficacy Endpoints At Two Year Analysis
Via Benzinga
BioMarin Class Action Reminder
Via NewMediaWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.